Form 4: Cytokinetics Director Wierenga Executes Option and Sells Shares
SEC Form 4
Wendall Wierenga, a director at Cytokinetics Inc, exercised stock options and sold shares on October 28, 2024, according to a Form 4 filing with the SEC.
Summary
- On October 28, 2024, Wendall Wierenga, a director of Cytokinetics Inc, executed a transaction involving the company's stock.
- Wierenga exercised a non-qualified stock option to acquire 4,452 shares of common stock at a price of $7.37 per share.
- Simultaneously, Wierenga sold 4,452 shares of common stock at a price of $52.25 per share.
- Following these transactions, Wierenga directly owns 24,559 shares of Cytokinetics Inc.
- Wierenga also holds options to purchase 1,484 shares.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it simply reports a transaction. It's neither positive nor negative from an investment perspective without additional context.
Industry Context
This filing is a routine disclosure of insider trading activity, which is common for directors and officers of publicly traded companies. It provides transparency to investors regarding the transactions of company insiders.
Stakeholder Impact
- The transaction could have a minor impact on shareholders, depending on their interpretation of the insider's actions.
Key Dates
| Date | Description |
|---|---|
| 02/02/2015 | Date from which the option began to vest in monthly installments. |
| 01/02/2016 | Date on which the option was 100% vested. |
| 01/02/2025 | Expiration date of the non-qualified stock option. |
| 10/28/2024 | Date of the transaction: exercise of stock options and sale of shares. |
| 10/31/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.